Proteonomix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROT research report →
About the company
Proteonomix, Inc. , a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue.
- CEO
- Michael Moshe Cohen
- IPO
- 1997
- Employees
- 164
- HQ
- Hawthorne, NJ, US
Price Chart
- Market Cap
- $791
- P/E
- -0.00
- P/S
- 0.03
- P/B
- -0.00
- EV/EBITDA
- -3.74
- Div Yield
- 0.00%
- Gross Margin
- 101.97%
- Op Margin
- -5026.15%
- Net Margin
- -5322.26%
- ROE
- 38.77%
- ROIC
- 604.70%
- Revenue
- $26.00K · -68.79%
- Net Income
- $-1,384,000 · 60.12%
- EPS
- $-0.21 · 72.00%
- Op Income
- $-1,307,000
- FCF YoY
- 59.58%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 15662.68
- Avg Volume
- 42.74K
Get TickerSpark's AI analysis on PROT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PROT coverage
Recent articles, reports, and earnings notes.
No research on PROT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PROT report →Similar companies
Peers in the same neighborhood.